The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Paul Gerard Guy Richardson

Dana-Farber Cancer Institute

Boston

MA 02215

USA

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Dana-Farber Cancer Institute, Boston, MA 02215, USA. 2001 - 2013
  • Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 2012 - 2013
  • Department of Adult Oncology, Harvard Medical School, Boston, USA. 2010
  • Harvard Medical School, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute, Boston, USA. 2010
  • Dana-Farber Cancer Institute, Department of Adult Oncology, Boston, Massahusetts 02115, USA. 2005 - 2010
  • Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, USA. 2002 - 2007
  • Department of Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 44 Binney Street, USA. 2006
  • Harvard Medical School, Boston, USA. 2003 - 2005
  • Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, 44 Binney Street, USA. 2005
  • Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Division of Hematologic Oncology, Dana 1B02, USA. 2004

References

  1. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Richardson, P.G., Mitsiades, C.S., Laubach, J.P., Hajek, R., Spicka, I., Dimopoulos, M.A., Moreau, P., Siegel, D.S., Jagannath, S., Anderson, K.C. Leuk. Res. (2013) [Pubmed]
  2. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Richardson, P.G., Siegel, D., Baz, R., Kelley, S.L., Munshi, N.C., Laubach, J., Sullivan, D., Alsina, M., Schlossman, R., Ghobrial, I.M., Doss, D., Loughney, N., McBride, L., Bilotti, E., Anand, P., Nardelli, L., Wear, S., Larkins, G., Chen, M., Zaki, M.H., Jacques, C., Anderson, K.C. Blood (2013) [Pubmed]
  3. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Richardson, P.G., Laubach, J.P., Schlossman, R.L., Ghobrial, I.M., Mitsiades, C.S., Rosenblatt, J., Mahindra, A., Raje, N., Munshi, N., Anderson, K.C. Eur. J. Haematol. (2012) [Pubmed]
  4. Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. Richardson, P.G., Wolf, J., Jakubowiak, A., Zonder, J., Lonial, S., Irwin, D., Densmore, J., Krishnan, A., Raje, N., Bar, M., Martin, T., Schlossman, R., Ghobrial, I.M., Munshi, N., Laubach, J., Allerton, J., Hideshima, T., Colson, K., Poradosu, E., Gardner, L., Sportelli, P., Anderson, K.C. J. Clin. Oncol. (2011) [Pubmed]
  5. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Richardson, P.G., Soiffer, R.J., Antin, J.H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P.L., Steinbach, G., Murray, K.F., Vogelsang, G.B., Chen, A.R., Krishnan, A., Kernan, N.A., Avigan, D.E., Spitzer, T.R., Shulman, H.M., Di Salvo, D.N., Revta, C., Warren, D., Momtaz, P., Bradwin, G., Wei, L.J., Iacobelli, M., McDonald, G.B., Guinan, E.C. Biol. Blood Marrow Transplant. (2010) [Pubmed]
  6. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Richardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L., Anderson, K.C. Blood (2010) [Pubmed]
  7. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Richardson, P.G., Laubach, J., Mitsiades, C., Schlossman, R.L., Doss, D., Colson, K., McKenney, M.L., Noonan, K., Warren, D.L., Ghobrial, I.M., Munshi, N.C., Anderson, K. Oncology (Williston Park, N.Y.) (2010) [Pubmed]
  8. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Richardson, P.G., Badros, A.Z., Jagannath, S., Tarantolo, S., Wolf, J.L., Albitar, M., Berman, D., Messina, M., Anderson, K.C. Br. J. Haematol. (2010) [Pubmed]
  9. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. Richardson, P.G., Laubach, J.P., Schlossman, R.L., Mitsiades, C., Anderson, K. J. Natl. Compr. Canc. Netw (2010) [Pubmed]
  10. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. Richardson, P.G., Weller, E., Jagannath, S., Avigan, D.E., Alsina, M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Ghobrial, I.M., Doss, D., Warren, D.L., Lunde, L.E., McKenney, M., Delaney, C., Mitsiades, C.S., Hideshima, T., Dalton, W., Knight, R., Esseltine, D.L., Anderson, K.C. J. Clin. Oncol. (2009) [Pubmed]
  11. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Richardson, P.G., Sonneveld, P., Schuster, M.W., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Bladé, J., Boccadoro, M., Cavenagh, J.D., Boral, A.L., Esseltine, D.L., Wen, P.Y., Amato, A.A., Anderson, K.C., San Miguel, J. Br. J. Haematol. (2009) [Pubmed]
  12. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Richardson, P.G., Xie, W., Mitsiades, C., Chanan-Khan, A.A., Lonial, S., Hassoun, H., Avigan, D.E., Oaklander, A.L., Kuter, D.J., Wen, P.Y., Kesari, S., Briemberg, H.R., Schlossman, R.L., Munshi, N.C., Heffner, L.T., Doss, D., Esseltine, D.L., Weller, E., Anderson, K.C., Amato, A.A. J. Clin. Oncol. (2009) [Pubmed]
  13. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S.F., Bensinger, W., Badros, A.Z., Vescio, R., Kenvin, L., Yu, Z., Olesnyckyj, M., Zeldis, J., Knight, R., Anderson, K.C. Blood (2009) [Pubmed]
  14. Bortezomib in the front-line treatment of multiple myeloma. Richardson, P.G., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Munshi, N., Anderson, K.C. Expert. Rev. Anticancer. Ther (2008) [Pubmed]
  15. The treatment of relapsed and refractory multiple myeloma. Richardson, P., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Chauhan, D., Munshi, N., Anderson, K. Hematology. Am. Soc. Hematol. Educ. Program (2007) [Pubmed]
  16. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., San Miguel, J.F., Cavenagh, J.D., Anderson, K.C. Br. J. Haematol. (2007) [Pubmed]
  17. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Miguel, J.S., Bladé, J., Boccadoro, M., Cavenagh, J., Alsina, M., Rajkumar, S.V., Lacy, M., Jakubowiak, A., Dalton, W., Boral, A., Esseltine, D.L., Schenkein, D., Anderson, K.C. Blood (2007) [Pubmed]
  18. The emerging role of novel therapies for the treatment of relapsed myeloma. Richardson, P.G., Hideshima, T., Mitsiades, C., Anderson, K.C. J. Natl. Compr. Canc. Netw (2007) [Pubmed]
  19. New drugs for myeloma. Richardson, P.G., Mitsiades, C., Schlossman, R., Munshi, N., Anderson, K. Oncologist (2007) [Pubmed]
  20. Bortezomib: proteasome inhibition as an effective anticancer therapy. Richardson, P.G., Mitsiades, C., Hideshima, T., Anderson, K.C. Annu. Rev. Med. (2006) [Pubmed]
  21. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D.H., Rajkumar, S.V., Srkalovic, G., Alsina, M., Anderson, K.C. Cancer (2006) [Pubmed]
  22. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C., Amato, A.A. J. Clin. Oncol. (2006) [Pubmed]
  23. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E., Anderson, K.C. Blood (2006) [Pubmed]
  24. Lenalidomide in multiple myeloma. Richardson, P.G., Mitsiades, C., Hideshima, T., Anderson, K.C. Expert. Rev. Anticancer. Ther (2006) [Pubmed]
  25. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Richardson, P.G., Mitsiades, C., Ghobrial, I., Anderson, K. Curr. Opin. Oncol (2006) [Pubmed]
  26. Proteasome inhibition in the treatment of cancer. Richardson, P.G., Mitsiades, C., Hideshima, T., Anderson, K.C. Cell. Cycle (2005) [Pubmed]
  27. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D., Anderson, K.C. N. Engl. J. Med. (2005) [Pubmed]
  28. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Hideshima, T., Xiao, H., Esseltine, D., Schenkein, D., Anderson, K.C. Blood (2005) [Pubmed]
  29. Novel biological therapies for the treatment of multiple myeloma. Richardson, P.G., Mitsiades, C.S., Hideshima, T., Anderson, K.C. Best. Pract. Res. Clin. Haematol (2005) [Pubmed]
  30. Emerging trends in the clinical use of bortezomib in multiple myeloma. Richardson, P.G., Schlossman, R., Mitsiades, C., Hideshima, T., Munshi, N., Anderson, K. Clinical. Lymphoma. &. Myeloma (2005) [Pubmed]
  31. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson, P. Semin. Hematol. (2005) [Pubmed]
  32. New treatments for multiple myeloma. Richardson, P.G., Schlossman, R., Hideshima, T., Anderson, K.C. Oncology (Williston Park, N.Y.) (2005) [Pubmed]
  33. Bortezomib: proteasome inhibition as an effective anticancer therapy. Richardson, P.G., Mitsiades, C. Future. Oncology. (london,. England) (2005) [Pubmed]
  34. An update of novel therapeutic approaches for multiple myeloma. Richardson, P., Hideshima, T., Anderson, K.C. Curr. Treat. Options. Oncol (2004) [Pubmed]
  35. A review of the proteasome inhibitor bortezomib in multiple myeloma. Richardson, P.G. Expert. Opin. Pharmacother (2004) [Pubmed]
  36. Proteasome inhibition in hematologic malignancies. Richardson, P.G., Hideshima, T., Mitsiades, C., Anderson, K. Ann. Med. (2004) [Pubmed]
  37. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Richardson, P., Schlossman, R., Jagannath, S., Alsina, M., Desikan, R., Blood, E., Weller, E., Mitsiades, C., Hideshima, T., Davies, F., Doss, D., Freeman, A., Bosch, J., Patin, J., Knight, R., Zeldis, J., Dalton, W., Anderson, K. Mayo Clin. Proc. (2004) [Pubmed]
  38. Clinical update: proteasome inhibitors in hematologic malignancies. Richardson, P. Cancer Treat. Rev. (2003) [Pubmed]
  39. A phase 2 study of bortezomib in relapsed, refractory myeloma. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P., Anderson, K.C. N. Engl. J. Med. (2003) [Pubmed]
  40. Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD. Richardson, P. Pathophysiol. Haemost. Thromb. (2003) [Pubmed]
  41. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Richardson, P.G., Hideshima, T., Anderson, K.C. Cancer. Control (2003) [Pubmed]
  42. Bortezomib: a novel therapy approved for multiple myeloma. Richardson, P.G., Anderson, K.C. Clin. Adv. Hematol. Oncol (2003) [Pubmed]
  43. Thalidomide: emerging role in cancer medicine. Richardson, P., Hideshima, T., Anderson, K. Annu. Rev. Med. (2002) [Pubmed]
  44. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Richardson, P.G., Murakami, C., Jin, Z., Warren, D., Momtaz, P., Hoppensteadt, D., Elias, A.D., Antin, J.H., Soiffer, R., Spitzer, T., Avigan, D., Bearman, S.I., Martin, P.L., Kurtzberg, J., Vredenburgh, J., Chen, A.R., Arai, S., Vogelsang, G., McDonald, G.B., Guinan, E.C. Blood (2002) [Pubmed]
  45. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Richardson, P., Guinan, E. Acta Haematol. (2001) [Pubmed]
 
WikiGenes - Universities